

## References

1. Denisyuk VI, Ivanov VP. Vinnitsa: Logos,2001.206p
2. Braunwald E. Biomarkers in heart failure. *N Engl J Med* 2008;20:2148–59.
3. Christenson RH, Duh SH, Wu AH, Smith A, Abel G, deFilippi CR, Wang S, Adourian A, Adiletto C, Gardiner P. Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. *Clin Biochem* 2010;43:683–90.
4. Christopher R de Filippi. Galectin-3 in Heart Failure – Linking Fibrosis, Remodeling, and Progression US Cardiology. Touch Briefing. *Heart Fail* 2010.p.67.
5. Felker GM, Fiuzat M, Shaw LK, Clare R, Whellan DJ, Bettari L, Shirolkar SC, Donahue M, Kitzman DW, Zannad F, Piña IL, O'Connor CM. Galectin-3 in Ambulatory Patients with Heart Failure: Results from the HF-ACTION Study. *Circ Heart Fail* 2011 Oct 20. [Epub ahead of print].
6. Iwanaga Y, Miyazaki S. Heart failure, chronic kidney disease, and biomarkers — an integrated viewpoint. *Circ J* 2010;74(7):1274–82.
7. Kramer F, Milting H. Novel biomarkers in human terminal heart failure and under mechanical circulatory support. *Biomarkers* 2011;Jul.16 (Suppl 1):31–41.
8. Lipkin D, Scriven A, Crake T, Poole-Wilson PA. Six minute walking test for assessing exercise capacity in chronic heart failure. *Brit Med J* 1986;292:653–6.
9. Lok D, van der Meer P, de La Porte PB, Lipsic E. Galectin-3, a novel marker of macrophage activity, predicts outcome in patients with stable chronic heart failure. *J Am Coll Cardiol* 2007;49(Suppl.A):98A [Abstract].